Deucrictibant Clinical Trials in HAE | Pharvaris
![](https://pharvaris.com/wp-content/uploads/2023/07/Circle-image-1-2.png)
Deucrictibant is designed to directly target the ultimate event in the HAE cascade, the interaction of bradykinin with the B2 receptor, a proven mechanism for the treatment of HAE attacks.
Pharvaris aims to bring better oral options to meet the needs of people with HAE for on-demand and prophylactic treatment. We are developing novel, potent and selective B2-receptor antagonist small molecules for the treatment of HAE.
People interested in participating in a clinical trial should speak with their physician.
![rapide-2 logo](https://pharvaris.com/wp-content/uploads/2023/06/rapid2-2-e1686166761417.png)
RAPIDe-2
Extension study of oral on-demand treatment
- For whom – people diagnosed with hereditary angioedema (HAE) who participated in RAPIDe-1
- Purpose – To further assess safety and efficacy of PHVS416 is in relieving symptoms associated with HAE attacks with long-term dosing.
- Approach – soft capsules taken orally to prevent HAE attacks.
![rapide-1 logo](https://pharvaris.com/wp-content/uploads/2023/06/RAPIDe-1_Logo-1024x417-2.png)
RAPIDe-1
Oral on-demand treatment study
- For whom – people diagnosed with hereditary angioedema (HAE).
- Purpose – To find out how effective PHVS416 is in relieving symptoms associated with HAE attacks.
- Approach – soft capsules taken orally to prevent HAE attacks.
For more information, visit the links below:
![chapter-1 logo](https://pharvaris.com/wp-content/uploads/2023/06/Chapter1_Logo_Primary_PMS-1.png)
CHAPTER-1
Oral prophylactic treatment study
- For whom – people diagnosed with hereditary angioedema (HAE).
- Purpose – to evaluate PHVS416 in preventing HAE attacks.
- Approach – soft capsules taken orally to prevent HAE attacks.
For more information, visit the links below: